TY - JOUR
AB - Reactions 1704, p259 - 2 Jun 2018 Stem cell mobilization failure : case report A 14-year-old girl experienced stem cell mobilization failure following treatment with vincristine, ifosfamide, doxorubicin, etoposide, cyclophosphamide, temozolomide, irinotecan and bevacizumab [time to reaction onset not stated]. The girl, who was diagnosed with extraosseus stage I Ewing’s sarcoma in April 2009, started receiving treatment with IV vincristine 1.5 mg/m on day 1, IV ifosfamide 2 2 3,000 mg/m on days 1–3, IV doxorubicin 20 mg/m on days 1–3, IV etoposide 150 mg/m on days 1–3 (every three weeks x 6 cycles). She completed 6 cycles prior to surgical resection. In October 2009, she received 8 cycles of consolidation with vincristine IV 1.5 mg/m2 on day 1, IV actinomycin (unspecified) 0.75 mg/m on days 1–2 and IV cyclophosphamide 1,500 mg/m on day 1 (every three weeks x 8 cycles). In April 2010, she developed early relapse and a second chemotherapy line was given with 5 cycles of oral temozolomide 100 mg/m on days 1–21, IV irinotecan 20 mg/m on days 1–5 and 8–13 and IV bevacizumab 350 mg/m on day 1 (every 21 days x 5 cycles). In July 2010, a second surgical resection plus radiotherapy localized 
TI - Multiple drugs
JF - Reactions Weekly
DO - 10.1007/s40278-018-46902-6
DA - 2018-06-02
UR - https://www.deepdyve.com/lp/springer-journals/multiple-drugs-COo0eVZvA0
SP - 259
EP - 259
VL - 1704
IS - 1
DP - DeepDyve